The board of directors of Ocumension Therapeutics announced that OT-202 (tyrosine kinase inhibitor), a class I new drug self-developed by the Company for the treatment of dry eye, has completed the enrollment of a total of 213 patients for the phase II clinical trial in China on November 21, 2023. OT-202 (tyrosine kinase inhibitor) is a class I innovative drug self-developed by the Company for the treatment of moderate to severe dry eye. The mechanism of action of OT-202 is that the dual-targeted inhibitor of spleen tyrosine kinase (Syk) and vascular endothelial growth factor receptor-2 achieves a synergistic effect in the treatment of dry eye diseases and inhibits the inflammatory response.

OT-202 demonstrated good safety and tolerability profile in healthy adult subjects in the phase I clinical trial successfully completed in February 2023. The phase II clinical trial of OT-202, which was launched in February 2023, is designed to be a randomized, double-masked, placebo-controlled clinical trial on the safety and efficacy of the drug.